MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Zentalis Pharmaceuticals Inc

Slēgts

1.55 -2.52

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.53

Max

1.67

Galvenie mērījumi

By Trading Economics

Ienākumi

21M

-27M

Peļņas marža

-176.706

Darbinieki

166

EBITDA

9.7M

-36M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+322.01% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 10. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

21M

121M

Iepriekšējā atvēršanas cena

4.07

Iepriekšējā slēgšanas cena

1.55

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 16. okt. 21:10 UTC

Galvenie tirgus virzītāji

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

2025. g. 16. okt. 19:03 UTC

Iegādes, apvienošanās, pārņemšana

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

2025. g. 16. okt. 17:58 UTC

Iegādes, apvienošanās, pārņemšana

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

2025. g. 16. okt. 17:12 UTC

Peļņas

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

2025. g. 16. okt. 17:12 UTC

Iegādes, apvienošanās, pārņemšana

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

2025. g. 16. okt. 16:59 UTC

Iegādes, apvienošanās, pārņemšana

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

2025. g. 16. okt. 23:44 UTC

Tirgus saruna

Gold Climbs Amid Safe-Haven Demand -- Market Talk

2025. g. 16. okt. 23:42 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

2025. g. 16. okt. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 16. okt. 22:15 UTC

Peļņas

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

2025. g. 16. okt. 22:15 UTC

Peļņas

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

2025. g. 16. okt. 22:15 UTC

Peļņas

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

2025. g. 16. okt. 22:02 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 16. okt. 22:02 UTC

Tirgus saruna

Santos Drifts Into 'Oversold Territory' -- Market Talk

2025. g. 16. okt. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 16. okt. 20:50 UTC

Tirgus saruna
Peļņas

Health Care Roundup: Market Talk

2025. g. 16. okt. 20:23 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 16. okt. 20:23 UTC

Tirgus saruna

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

2025. g. 16. okt. 20:20 UTC

Peļņas

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

2025. g. 16. okt. 20:08 UTC

Iegādes, apvienošanās, pārņemšana

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

2025. g. 16. okt. 19:37 UTC

Iegādes, apvienošanās, pārņemšana

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

2025. g. 16. okt. 19:26 UTC

Peļņas

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

2025. g. 16. okt. 19:24 UTC

Tirgus saruna

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

2025. g. 16. okt. 19:23 UTC

Tirgus saruna

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

2025. g. 16. okt. 19:23 UTC

Peļņas

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

2025. g. 16. okt. 18:35 UTC

Tirgus saruna
Peļņas

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

2025. g. 16. okt. 18:31 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 16. okt. 18:31 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 16. okt. 18:31 UTC

Tirgus saruna

Charles Schwab Readies Spot Crypto Trading -- Market Talk

2025. g. 16. okt. 16:57 UTC

Tirgus saruna

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

322.01% augšup

Prognoze 12 mēnešiem

Vidējais 6.71 USD  322.01%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

4

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat